MALAT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Another recent finding reports that lncRNA MALAT1/miR-328 axis promotes the proliferation and imatinib resistance of CML cells, providing new perspectives for the future study of MALAT1 as a therapeutic target for CML [40].